Visit main University website

University of Sydney logo

Find MND Biomarker

University of Sydney logo

Find MND Biomarker

↑

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI:

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 

DOI: https://doi.org/10.1002/ana.27300

Contact: For help contact [email protected]
Sort by:
Total Records Found: 4574, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
PODN Q7Z5L7 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Down 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
PNPT1 Q8TCS8 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
PNP P00491 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PNP P00491 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PNOC P01259 Vu et al. 2023 ALS fast ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
PNOC Q13519 Trautwig et al. 2025 Sporadic ALS Control CSF Down 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
PMPCA Q10713 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PMM1 Q92871 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PLXNB3 Q9ULL4 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
PLXNB1 O43157 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLXNA4 Q9HCM2 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PLXNA2 O75051 Trautwig et al. 2025 Sporadic ALS Control CSF Down 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
PLXNA2 O75051 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
PLXNA2 O75051 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PLXDC2 Q6UX71 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLXDC2 Q6UX71 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PLXDC1 Q8IUK5 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLXDC1 Q8IUK5 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PLTP P55058 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLTP P55058 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
PLSI Q14651 Andrés-Benito et al. 2020 ALS Control CSF Down 15 ALS, 15 control N/A 61 ± 10.8 N/A
PLSCR4 Q9NRQ2 Vassileff et al. 2020 ALS Control Motor Cortex EVs Down 7 ALS, 3 control N/A N/A N/A
PLS1 Q14651 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PLP1 P60201 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
PLP1 P60201 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PLK1 P53350 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
PLG P00747 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
PLG P00747 Xu et al. 2018 ALS Control Plasma Down 42 ALS, 18 control N/A 61.8 ± 9.6 N/A
PLF4 P02776 Oh et al. 2023 ALS Control CSF Up 20 ALS, 20 control N/A 59 N/A
PLEKHO2 Q8TD55 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PLEKHB1 F5H1B8 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PLEKHB1 Q9UF11 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
PLEKHB1 Q9UF11 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PLEKHB1 Q9UF11 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PLEKHB1 Q9UF11 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLEK P08567 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PLEC Q15149 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
PLD4 Q96BZ4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLD3 Q8IV08 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
PLD3 Q8IV08 Bereman et al. 2018 ALS Control CSF Down 33 ALS, 30 control N/A N/A N/A
PLCXD3 Q63HM9 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PLCD4 Q9BRC7 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PLCB1 Q9NQ66 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PLCB1 Q9NQ66 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PLAUR Q03405 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PLAK P14923 Vilardo et al. 2024 ALS (discovery cohort) Control (discovery cohort) Plasma EVs Down 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
PLA2G7 Q13093 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PLA2G7 Q13093 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PLA2G15 Q8NCC3 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PKM P14618 Filareti et al. 2017 Late ALS Early ALS PBMCs Up 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
PKDCC Q504Y2 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
PITHD1 Q9GZP4 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PITHD1 Q9GZP4 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PITHD1 Q9GZP4 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PITH1 Q9GZP4 Andrés-Benito et al. 2020 ALS Control CSF Down 15 ALS, 15 control N/A 61 ± 10.8 N/A
PIP5K1C O60331 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PIP5K1C O60331 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PIP4K2C Q8TBX8 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PIN1 K7EN45 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PIN1 Q13526 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PIN1 Q13526 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
PILRA Q9UKJ1 Zhou et al. 2023 BO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
PIK3IP1 Q96FE7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PIGR P01833 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
PIGR P01833 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PIGR P01833 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PICK1 Q9NRD5 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
PIANP Q8IYJ0 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
PI16 Q6UXB8 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
PI16 Q6UXB8 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PI16 Q6UXB8 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
PI16 Q6UXB8 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PHYHIP Q92561 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PHPT1 Q9NRX4 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PHPT1 Q9NRX4 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PHPT1 Q9NRX4 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
PHGDH O43175 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
PHF5A Q7RTV0 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
PHB2 J3KPX7 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PHB2 Q99623 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PHB1 P35232 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PHB P35232 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PHB P35232 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
PGRMC2 O15173 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
PGP A6NDG6 Andrés-Benito et al. 2020 ALS Control CSF Up 15 ALS, 15 control N/A 61 ± 10.8 N/A
PGP A6NDG6 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
PGM1 P36871 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PGLYRP2 Q96PD5 Vu et al. 2023 ALS fast ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow) N/A
PGLYRP2 Q96PD5 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PGLYRP2 Q96PD5 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
PGLYRP2 Q96PD5 Oeckl et al. 2020 ALS Control CSF Up 26 ALS, 16 control N/A N/A N/A
PGLS O95336 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
PGLS O95336 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PGLS O95336 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
PGLS O95336 Filareti et al. 2017 Late ALS Early ALS PBMCs Up 16 Early-ALS, 16 Late-ALS N/A 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS) N/A
PGLS O95336 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
PGK1 P00558 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
PGK1 P00558 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
PGK1 P00558 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
PGK1 P00558 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A